MaRS Innovation’s ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.

Read the article on Globe and Mail.com (note that depending on when you’re accessing this page, the Globe‘s content may be subject to a pay wall).

Each year, approximately 240 million surgeries are performed worldwide. Market research suggests an effective anti‐skin‐scarring therapeutic represents a multi-billion dollar opportunity.

Currently, no clinically-proven prescription therapeutic can prevent excessive dermal scarring. ScarX Therapeutics seeks to change that.

ScarX developed out of Dr. Benjamin Alman‘s research at SickKids.

Dr. Alman is also the A.J. Latner professor and chair of Orthopaedics at the University of Toronto, vice-chair research of the department of Surgery, and the interim head of the Toronto Musculoskeletal Center.

He is a Canada Research Chair.

Posted by Elizabeth Monier-Williams, marketing and communications manager.